1. Início
  2. Hospital das Clínicas da Faculdade de Medicina - HC
  3. Instituto do Câncer do Estado de São Paulo - HC/ICESP
  4. Artigos e Materiais de Revistas Científicas - HC/ICESP
Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/37111
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGALLUZZI, Lorenzo
dc.contributor.authorVITALE, Ilio
dc.contributor.authorWARREN, Sarah
dc.contributor.authorADJEMIAN, Sandy
dc.contributor.authorAGOSTINIS, Patrizia
dc.contributor.authorMARTINEZ, Aitziber Buque
dc.contributor.authorCHAN, Timothy A.
dc.contributor.authorCOUKOS, George
dc.contributor.authorDEMARIA, Sandra
dc.contributor.authorDEUTSCH, Eric
dc.contributor.authorDRAGANOV, Dobrin
dc.contributor.authorEDELSON, Richard L.
dc.contributor.authorFORMENTI, Silvia C.
dc.contributor.authorFUCIKOVA, Jitka
dc.contributor.authorGABRIELE, Lucia
dc.contributor.authorGAIPL, Udo S.
dc.contributor.authorGAMEIRO, Sofia R.
dc.contributor.authorGARG, Abhishek D.
dc.contributor.authorGOLDEN, Encouse
dc.contributor.authorHAN, Jian
dc.contributor.authorHARRINGTON, Kevin J.
dc.contributor.authorHEMMINKI, Akseli
dc.contributor.authorHODGE, James W.
dc.contributor.authorHOSSAIN, Dewan Md Sakib
dc.contributor.authorILLIDGE, Tim
dc.contributor.authorKARIN, Michael
dc.contributor.authorKAUFMAN, Howard L.
dc.contributor.authorKEPP, Oliver
dc.contributor.authorKROEMER, Guido
dc.contributor.authorLASARTE, Juan Jose
dc.contributor.authorLOI, Sherene
dc.contributor.authorLOTZE, Michael T.
dc.contributor.authorMANIC, Gwenola
dc.contributor.authorMERGHOUB, Taha
dc.contributor.authorMELCHER, Alan A.
dc.contributor.authorMOSSMAN, Karen L.
dc.contributor.authorPROSPER, Felipe
dc.contributor.authorREKDAL, Oystein
dc.contributor.authorRESCIGNO, Maria
dc.contributor.authorRIGANTI, Chiara
dc.contributor.authorSISTIGU, Antonella
dc.contributor.authorSMYTH, Mark J.
dc.contributor.authorSPISEK, Radek
dc.contributor.authorSTAGG, John
dc.contributor.authorSTRAUSS, Bryan E.
dc.contributor.authorTANG, Daolin
dc.contributor.authorTATSUNO, Kazuki
dc.contributor.authorGOOL, Stefaan W. van
dc.contributor.authorVANDENABEELE, Peter
dc.contributor.authorYAMAZAKI, Takahiro
dc.contributor.authorZAMARIN, Dmitriy
dc.contributor.authorZITVOGEL, Laurence
dc.contributor.authorCESANO, Alessandra
dc.contributor.authorMARINCOLA, Francesco M.
dc.date.accessioned2020-08-20T13:27:07Z-
dc.date.available2020-08-20T13:27:07Z-
dc.date.issued2020
dc.identifier.citationJOURNAL FOR IMMUNOTHERAPY OF CANCER, v.8, n.1, article ID e000337, 21p, 2020
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37111-
dc.description.abstractCells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.eng
dc.description.sponsorshipUS Department of Defense (DoD)United States Department of Defense
dc.description.sponsorshipBreast Cancer Research Program (BRCP) [BC180476P1]
dc.description.sponsorshipDept. of Radiation Oncology at Weill Cornell Medicine
dc.description.sponsorshipAssociazione Italiana per la Ricerca sul Cancro (AIRC, IG))Associazione Italiana per la Ricerca sul Cancro (AIRC) [20417]
dc.description.sponsorshipItalian Institute for Genomic Medicine (Candiolo, Turin, Italy)
dc.description.sponsorshipCompagnia di San Paolo (Turin, Italy)Compagnia di San Paolo
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUPeng
dc.relation.ispartofJournal for Immunotherapy of Cancer
dc.rightsopenAccesseng
dc.subjectoncologyeng
dc.subjectimmunologyeng
dc.subjectmolecular biologyeng
dc.subject.otherpattern-recognition receptorseng
dc.subject.otherimmune checkpoint blockadeeng
dc.subject.othernod-like receptorseng
dc.subject.othernf-kappa-beng
dc.subject.othercalreticulin exposureeng
dc.subject.othercancer-cellseng
dc.subject.otherantitumor immunityeng
dc.subject.otherapoptotic cellseng
dc.subject.otheranticancer chemotherapyeng
dc.subject.otherantigen presentationeng
dc.titleConsensus guidelines for the definition, detection and interpretation of immunogenic cell deatheng
dc.typearticleeng
dc.rights.holderCopyright BMJ PUBLISHING GROUPeng
dc.identifier.doi10.1136/jitc-2019-000337
dc.identifier.pmid32209603
dc.subject.wosOncologyeng
dc.subject.wosImmunologyeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalGALLUZZI, Lorenzo:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA; Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA; Caryl & Israel Englander Inst Precis Med, New York, NY 10065 USA; Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Univ Paris, Paris, France
hcfmusp.author.externalVITALE, Ilio:IIGM Italian Inst Genom Med, IRCSS, Turin, Italy; FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy
hcfmusp.author.externalWARREN, Sarah:NanoString Technol, Seattle, WA USA
hcfmusp.author.externalADJEMIAN, Sandy:VIB Ctr Inflammat Res IRC, Ghent, Belgium; Univ Ghent, Dept Biomed Mol Biol DBMB, Ghent, Belgium
hcfmusp.author.externalAGOSTINIS, Patrizia:Katholieke Univ Leuven, Cell Death Res & Therapy CDRT Lab, Dept Cellular & Mol Med, Leuven, Belgium; KU Leuevn, VIB KU Leuven Ctr Canc Biol, Leuven, Belgium
hcfmusp.author.externalMARTINEZ, Aitziber Buque:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
hcfmusp.author.externalCHAN, Timothy A.:Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA
hcfmusp.author.externalCOUKOS, George:Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; Univ Lausanne, Dept Oncol, Lausanne, Switzerland
hcfmusp.author.externalDEMARIA, Sandra:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA; Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA; Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
hcfmusp.author.externalDEUTSCH, Eric:Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France; Gustave Roussy Canc Campus, INSERM Mol Radiotherapy & Therapeut Innovat, U1030 Mol Radiotherapy, Villejuif, France; Univ Paris Saclay, Fac Med, SIRIC SOCRATES, DHU Torino, Le Kremlin Bicetre, France
hcfmusp.author.externalDRAGANOV, Dobrin:Calidi Biotherapeut, San Diego, CA USA
hcfmusp.author.externalEDELSON, Richard L.:Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Comprehens Canc Ctr, New Haven, CT USA
hcfmusp.author.externalFORMENTI, Silvia C.:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA; Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA
hcfmusp.author.externalFUCIKOVA, Jitka:Charles Univ Prague, Dept Immunol, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic
hcfmusp.author.externalGABRIELE, Lucia:Ist Super Sanit, Dept Oncol & Mol Med, Rome, Italy
hcfmusp.author.externalGAIPL, Udo S.:Univ Klinikum Erlangen, Erlangen, Germany
hcfmusp.author.externalGAMEIRO, Sofia R.:NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
hcfmusp.author.externalGARG, Abhishek D.:Katholieke Univ Leuven, Cell Death Res & Therapy CDRT Lab, Dept Cellular & Mol Med, Leuven, Belgium
hcfmusp.author.externalGOLDEN, Encouse:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA; Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA
hcfmusp.author.externalHAN, Jian:iRepertoire Inc, Huntsville, AL USA
hcfmusp.author.externalHARRINGTON, Kevin J.:Inst Canc Res, Div Radiotherapy & Imaging, London, England; Royal Marsden Hosp, Natl Inst Hlth, Biomed Res Ctr, Inst Canc Res, London, England
hcfmusp.author.externalHEMMINKI, Akseli:Univ Helsinki, Translat Immunol Res Program, Canc Gene Therapy Grp, Helsinki, Finland; Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
hcfmusp.author.externalHODGE, James W.:NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
hcfmusp.author.externalHOSSAIN, Dewan Md Sakib:Merck & Co Inc, Kenilworth, NJ USA
hcfmusp.author.externalILLIDGE, Tim:Univ Manchester, Christie Hosp, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England
hcfmusp.author.externalKARIN, Michael:Univ Calif San Diego, Sch Med, Dept Pharmacol & Pathol, La Jolla, CA 92093 USA
hcfmusp.author.externalKAUFMAN, Howard L.:Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Replimune Inc, Woburn, MA USA
hcfmusp.author.externalKEPP, Oliver:Gustave Roussy Comprehens Canc Inst, Metabol & Cell Biol Platforms, Villejuif, France; Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France
hcfmusp.author.externalKROEMER, Guido:Univ Paris, Paris, France; Gustave Roussy Comprehens Canc Inst, Metabol & Cell Biol Platforms, Villejuif, France; Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France; Gustave Roussy Comprehens Canc Inst, Villejuif, France; INSERM, U1138, Paris, France; Sorbonne Univ, Paris, France; Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden; Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Peoples R China
hcfmusp.author.externalLASARTE, Juan Jose:Univ Navarra, Ctr Invest Mea Aplicada CIMA, Program Immunol & Immunotherapy, Pamplona, Spain
hcfmusp.author.externalLOI, Sherene:Peter MacCallum Canc Ctr, Div Res & Clin Med, Melbourne, Vic, Australia; Univ Melbourne, Dept Oncol, Parkville, Vic, Australia
hcfmusp.author.externalLOTZE, Michael T.:Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Bioengn, Pittsburgh, PA USA
hcfmusp.author.externalMANIC, Gwenola:IIGM Italian Inst Genom Med, IRCSS, Turin, Italy; FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy
hcfmusp.author.externalMERGHOUB, Taha:MSKCC, Ludwig Collaborat & Swim Amer Lab, New York, NY USA; Weill Cornell Med Coll, New York, NY USA; MSKCC, Parker Inst Canc Immunotherapy, New York, NY USA
hcfmusp.author.externalMELCHER, Alan A.:Inst Canc Res, London, England
hcfmusp.author.externalMOSSMAN, Karen L.:McMaster Univ, Hamilton, ON, Canada
hcfmusp.author.externalPROSPER, Felipe:Clin Univ Navarra, Hematol & Cell Therapy, Pamplona, Spain
hcfmusp.author.externalREKDAL, Oystein:Lytix Biopharma, Oslo, Norway; Univ Tromso, Dept Med Biol, Tromso, Norway
hcfmusp.author.externalRESCIGNO, Maria:IRCCS, Humanitas Clin & Res Ctr, Rozzano, Italy; Humanitas Univ, Dept Biomed Sci, Milan, Italy
hcfmusp.author.externalRIGANTI, Chiara:Univ Torino, Dept Oncol, Turin, Italy; Univ Torino, Interdept Res Ctr Mol Biotechnol, Turin, Italy
hcfmusp.author.externalSISTIGU, Antonella:IRCCS Regina Elena Natl Canc Ctr, UOSD Immunol & Immunotherapy Unit, Rome, Italy; Univ Cattolica Sacro Cuore, Ist Patol Gen, Rome, Italy
hcfmusp.author.externalSMYTH, Mark J.:QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia
hcfmusp.author.externalSPISEK, Radek:Charles Univ Prague, Dept Immunol, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; Sotio, Prague, Czech Republic
hcfmusp.author.externalSTAGG, John:Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ, Canada; Inst Canc Montreal, Montreal, PQ, Canada; Univ Montreal, Fac Pharm, Montreal, PQ, Canada
hcfmusp.author.externalTANG, Daolin:UT Southwestern Med Ctr, Dept Surg, Dallas, TX USA
hcfmusp.author.externalTATSUNO, Kazuki:Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA
hcfmusp.author.externalGOOL, Stefaan W. van:Immun Onkol Zentrum Koln, Cologne, Germany
hcfmusp.author.externalVANDENABEELE, Peter:VIB Ctr Inflammat Res IRC, Ghent, Belgium; Univ Ghent, Dept Biomed Mol Biol DBMB, Ghent, Belgium; Univ Ghent, Methusalem Program, Ghent, Belgium
hcfmusp.author.externalYAMAZAKI, Takahiro:Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
hcfmusp.author.externalZAMARIN, Dmitriy:Weill Cornell Med Coll, Dept Med, New York, NY USA; Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
hcfmusp.author.externalZITVOGEL, Laurence:Gustave Roussy Comprehens Canc Inst, Villejuif, France; Gustave Roussy, Equipe Labellisee Ligue Ctr Canc, Villejuif, France; Univ Paris Sud Paris Saclay, Fac Med, Le Kremlin Bicetre, France; INSERM U1015, Villejuif, France; Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France
hcfmusp.author.externalCESANO, Alessandra:ESSA Pharmaceut, San Francisco, CA USA
hcfmusp.author.externalMARINCOLA, Francesco M.:Refuge Biotechnol, Menlo Pk, CA USA
hcfmusp.description.articlenumbere000337
hcfmusp.description.issue1
hcfmusp.description.volume8
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000534745200010
hcfmusp.origem.id2-s2.0-85081610705
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAaes TL, 2016, CELL REP, V15, P274, DOI 10.1016/j.celrep.2016.03.037eng
hcfmusp.relation.referenceAblasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657eng
hcfmusp.relation.referenceAdkins I, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1311433eng
hcfmusp.relation.referenceAhrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008eng
hcfmusp.relation.referenceAlarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011eng
hcfmusp.relation.referenceAlexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477eng
hcfmusp.relation.referenceAli N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044219eng
hcfmusp.relation.referenceApetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.xeng
hcfmusp.relation.referenceApetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622eng
hcfmusp.relation.referenceAranda F, 2015, ONCOGENE, V34, P3053, DOI 10.1038/onc.2014.234eng
hcfmusp.relation.referenceBalachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462eng
hcfmusp.relation.referenceBantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99eng
hcfmusp.relation.referenceBauer C, 2007, GUT, V56, P1275, DOI 10.1136/gut.2006.108621eng
hcfmusp.relation.referenceBezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506eng
hcfmusp.relation.referenceBezu L, 2018, CELL DEATH DIFFER, V25, P1375, DOI 10.1038/s41418-017-0044-9eng
hcfmusp.relation.referenceBianchi ME, 2017, IMMUNOL REV, V280, P74, DOI 10.1111/imr.12601eng
hcfmusp.relation.referenceBidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830eng
hcfmusp.relation.referenceBillerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507eng
hcfmusp.relation.referenceBloy N, 2017, IMMUNOL REV, V280, P165, DOI 10.1111/imr.12582eng
hcfmusp.relation.referenceBondanza A, 2004, J EXP MED, V200, P1157, DOI 10.1084/jem.20040327eng
hcfmusp.relation.referenceBonnotte B, 2003, CANCER RES, V63, P2145eng
hcfmusp.relation.referenceBoone BA, 2015, CANCER GENE THER, V22, P326, DOI 10.1038/cgt.2015.21eng
hcfmusp.relation.referenceBoyd-Tressler A, 2014, J BIOL CHEM, V289, P27246, DOI 10.1074/jbc.M114.590240eng
hcfmusp.relation.referenceBraciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109eng
hcfmusp.relation.referenceBriere D, 2018, CANCER IMMUNOL IMMUN, V67, P381, DOI 10.1007/s00262-017-2091-yeng
hcfmusp.relation.referenceBrown MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan4220eng
hcfmusp.relation.referenceBroz P, 2013, NAT REV IMMUNOL, V13, P551, DOI 10.1038/nri3479eng
hcfmusp.relation.referenceBugaut H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065181eng
hcfmusp.relation.referenceBuque A, 2018, TRENDS CANCER, V4, P599, DOI 10.1016/j.trecan.2018.07.003eng
hcfmusp.relation.referenceCampbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048eng
hcfmusp.relation.referenceCampisi L, 2016, NAT IMMUNOL, V17, P1084, DOI 10.1038/ni.3512eng
hcfmusp.relation.referenceCao XT, 2016, NAT REV IMMUNOL, V16, P35, DOI 10.1038/nri.2015.8eng
hcfmusp.relation.referenceCasares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915eng
hcfmusp.relation.referenceCekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4eng
hcfmusp.relation.referenceChabanon RM, 2019, J CLIN INVEST, V129, P1211, DOI 10.1172/JCI123319eng
hcfmusp.relation.referenceChang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016eng
hcfmusp.relation.referenceChao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375eng
hcfmusp.relation.referenceChen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349eng
hcfmusp.relation.referenceChen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012eng
hcfmusp.relation.referenceChen HM, 2012, CANCER IMMUNOL IMMUN, V61, P1989, DOI 10.1007/s00262-012-1258-9eng
hcfmusp.relation.referenceChen XF, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1278332eng
hcfmusp.relation.referenceChiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376eng
hcfmusp.relation.referenceChow KT, 2018, ANNU REV IMMUNOL, V36, P667, DOI 10.1146/annurev-immunol-042617-053309eng
hcfmusp.relation.referenceChristiansen AJ, 2011, P NATL ACAD SCI USA, V108, P4141, DOI 10.1073/pnas.1011037108eng
hcfmusp.relation.referenceChu HT, 2013, NAT IMMUNOL, V14, P668, DOI 10.1038/ni.2635eng
hcfmusp.relation.referenceColangelo T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.29eng
hcfmusp.relation.referenceColegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490eng
hcfmusp.relation.referenceCoulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670eng
hcfmusp.relation.referenced'Almeida SM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1178025eng
hcfmusp.relation.referenceD'Eliseo D, 2013, CELL STRESS CHAPERON, V18, P801, DOI 10.1007/s12192-013-0422-2eng
hcfmusp.relation.referencedel Barrio IM, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0154-9eng
hcfmusp.relation.referenceDemaria S, 2005, CLIN CANCER RES, V11, P728eng
hcfmusp.relation.referenceDeng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019eng
hcfmusp.relation.referenceDeutsch E, 2019, LANCET ONCOL, V20, pE452, DOI 10.1016/S1470-2045(19)30171-8eng
hcfmusp.relation.referenceDewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265eng
hcfmusp.relation.referenceDi Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0eng
hcfmusp.relation.referenceDiaconu I, 2012, CANCER RES, V72, P2327, DOI 10.1158/0008-5472.CAN-11-2975eng
hcfmusp.relation.referenceDiamond JM, 2018, CANCER IMMUNOL RES, V6, P910, DOI 10.1158/2326-6066.CIR-17-0581eng
hcfmusp.relation.referenceDillon MT, 2019, CLIN CANCER RES, V25, P3392, DOI 10.1158/1078-0432.CCR-18-1821eng
hcfmusp.relation.referenceDinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621eng
hcfmusp.relation.referenceDiner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009eng
hcfmusp.relation.referenceDonnelly OG, 2013, GENE THER, V20, P7, DOI 10.1038/gt.2011.205eng
hcfmusp.relation.referenceDorhoi A, 2009, CURR OPIN IMMUNOL, V21, P367, DOI 10.1016/j.coi.2009.07.004eng
hcfmusp.relation.referenceDoyle HA, 2012, CURR OPIN IMMUNOL, V24, P112, DOI 10.1016/j.coi.2011.12.003eng
hcfmusp.relation.referenceDudek-Peric AM, 2015, CANCER RES, V75, P1603, DOI 10.1158/0008-5472.CAN-14-2089eng
hcfmusp.relation.referenceDuewell P, 2014, CELL DEATH DIFFER, V21, P1825, DOI 10.1038/cdd.2014.96eng
hcfmusp.relation.referenceDuewell P, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1029698eng
hcfmusp.relation.referenceElliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296eng
hcfmusp.relation.referenceFend L, 2017, CANCER RES, V77, P4146, DOI 10.1158/0008-5472.CAN-16-2165eng
hcfmusp.relation.referenceFlavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808eng
hcfmusp.relation.referenceFormenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2eng
hcfmusp.relation.referenceForveille S, 2015, CELL CYCLE, V14, P3506, DOI 10.1080/15384101.2015.1093710eng
hcfmusp.relation.referenceFragale A, 2017, CANCER IMMUNOL RES, V5, P604, DOI 10.1158/2326-6066.CIR-17-0080eng
hcfmusp.relation.referenceFridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101eng
hcfmusp.relation.referenceFuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033eng
hcfmusp.relation.referenceFucikova J, 2018, IMMUNOL LETT, V193, P25, DOI 10.1016/j.imlet.2017.11.006eng
hcfmusp.relation.referenceFucikova J, 2016, BLOOD, V128, P3113, DOI [10.1182/blood-2016-08731737, 10.1182/blood-2016-08-731737]eng
hcfmusp.relation.referenceFucikova J, 2016, CANCER RES, V76, P1746, DOI 10.1158/0008-5472.CAN-15-1142eng
hcfmusp.relation.referenceFucikova J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00402eng
hcfmusp.relation.referenceFucikova J, 2014, INT J CANCER, V135, P1165, DOI 10.1002/ijc.28766eng
hcfmusp.relation.referenceFucikova J, 2011, CANCER RES, V71, P4821, DOI 10.1158/0008-5472.CAN-11-0950eng
hcfmusp.relation.referenceFung TC, 2017, NAT NEUROSCI, V20, P145, DOI 10.1038/nn.4476eng
hcfmusp.relation.referenceGalluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137eng
hcfmusp.relation.referenceGalluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44eng
hcfmusp.relation.referenceGalluzzi L, 2018, NAT REV MOL CELL BIO, V19, P731, DOI 10.1038/s41580-018-0068-0eng
hcfmusp.relation.referenceGalluzzi L, 2018, CELL, V173, DOI 10.1016/j.cell.2018.03.015eng
hcfmusp.relation.referenceGalluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4eng
hcfmusp.relation.referenceGalluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697eng
hcfmusp.relation.referenceGalluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107eng
hcfmusp.relation.referenceGalluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012eng
hcfmusp.relation.referenceGaluschka C, 2017, CANCER RES, V77, P2557, DOI 10.1158/0008-5472.CAN-16-3099eng
hcfmusp.relation.referenceGameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719eng
hcfmusp.relation.referenceGardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032eng
hcfmusp.relation.referenceGarg A. D., 2016, SCI TRANSL MED, V8eng
hcfmusp.relation.referenceGarg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588eng
hcfmusp.relation.referenceGarg AD, 2017, IMMUNOL REV, V280, P126, DOI 10.1111/imr.12574eng
hcfmusp.relation.referenceGarg AD, 2017, CELL DEATH DIFFER, V24, P832, DOI 10.1038/cdd.2017.15eng
hcfmusp.relation.referenceGarg AD, 2015, ONCOTARGET, V6, P26841, DOI 10.18632/oncotarget.4754eng
hcfmusp.relation.referenceGarg AD, 2013, AUTOPHAGY, V9, P1292, DOI 10.4161/auto.25399eng
hcfmusp.relation.referenceGarg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497eng
hcfmusp.relation.referenceGarg AD, 2012, CANCER IMMUNOL IMMUN, V61, P215, DOI 10.1007/s00262-011-1184-2eng
hcfmusp.relation.referenceGarrido F, 2016, CURR OPIN IMMUNOL, V39, P44, DOI 10.1016/j.coi.2015.12.007eng
hcfmusp.relation.referenceGay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713eng
hcfmusp.relation.referenceGengenbacher N, 2017, NAT REV CANCER, V17, P751, DOI 10.1038/nrc.2017.92eng
hcfmusp.relation.referenceGhiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028eng
hcfmusp.relation.referenceGilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6eng
hcfmusp.relation.referenceGoel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465eng
hcfmusp.relation.referenceGolden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518eng
hcfmusp.relation.referenceGolden EB, 2013, CANCER IMMUNOL RES, V1, P365, DOI 10.1158/2326-6066.CIR-13-0115eng
hcfmusp.relation.referenceGoldszmid RS, 2014, CELL HOST MICROBE, V15, P295, DOI 10.1016/j.chom.2014.02.003eng
hcfmusp.relation.referenceGopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015eng
hcfmusp.relation.referenceGorgulho CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01561eng
hcfmusp.relation.referenceGrasso CS, 2018, CANCER DISCOV, V8, P730, DOI 10.1158/2159-8290.CD-17-1327eng
hcfmusp.relation.referenceGreaves M, 2015, CANCER DISCOV, V5, P806, DOI 10.1158/2159-8290.CD-15-0439eng
hcfmusp.relation.referenceGreen DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256eng
hcfmusp.relation.referenceGreen DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545eng
hcfmusp.relation.referenceGrimaldi AM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28780eng
hcfmusp.relation.referenceGuo SQ, 2018, INT J CANCER, V142, P629, DOI 10.1002/ijc.31071eng
hcfmusp.relation.referenceHalkias J, 2015, IMMUNOL CELL BIOL, V93, P716, DOI 10.1038/icb.2015.38eng
hcfmusp.relation.referenceHangai S, 2016, P NATL ACAD SCI USA, V113, P3844, DOI 10.1073/pnas.1602023113eng
hcfmusp.relation.referenceHartmann J, 2016, STRAHLENTHER ONKOL, V192, P806, DOI 10.1007/s00066-016-1014-8eng
hcfmusp.relation.referenceHellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946eng
hcfmusp.relation.referenceHellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001eng
hcfmusp.relation.referenceHirvinen M, 2015, HUM GENE THER, V26, P134, DOI 10.1089/hum.2014.069eng
hcfmusp.relation.referenceHo WS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04425-zeng
hcfmusp.relation.referenceHossain DMS, 2018, J CLIN INVEST, V128, P644, DOI 10.1172/JCI94586eng
hcfmusp.relation.referenceHou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.493eng
hcfmusp.relation.referenceImamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106eng
hcfmusp.relation.referenceIshak CA, 2018, TRENDS CANCER, V4, P583, DOI 10.1016/j.trecan.2018.05.008eng
hcfmusp.relation.referenceIto R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543eng
hcfmusp.relation.referenceIwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123eng
hcfmusp.relation.referenceJones PA, 2019, NAT REV CANCER, V19, P151, DOI 10.1038/s41568-019-0109-9eng
hcfmusp.relation.referenceJuste Y R, 2019, Methods Mol Biol, V1880, P703, DOI 10.1007/978-1-4939-8873-0_47eng
hcfmusp.relation.referenceKanaseki T, 2019, PATHOL INT, V69, P511, DOI 10.1111/pin.12841eng
hcfmusp.relation.referenceKang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631eng
hcfmusp.relation.referenceKang R, 2016, J IMMUNOL, V196, P4331, DOI 10.4049/jimmunol.1502340eng
hcfmusp.relation.referenceKawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006eng
hcfmusp.relation.referenceKawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863eng
hcfmusp.relation.referenceKemp CJ, 2015, COLD SPRING HARB PRO, V2015, DOI 10.1101/pdb.top069906eng
hcfmusp.relation.referenceKepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691eng
hcfmusp.relation.referenceKepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373eng
hcfmusp.relation.referenceKersse K, 2011, CYTOKINE GROWTH F R, V22, P257, DOI 10.1016/j.cytogfr.2011.09.003eng
hcfmusp.relation.referenceKersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857eng
hcfmusp.relation.referenceKirkin AF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03217-9eng
hcfmusp.relation.referenceKlein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667eng
hcfmusp.relation.referenceKlionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356eng
hcfmusp.relation.referenceKo Eric C, 2018, Adv Radiat Oncol, V3, P486, DOI 10.1016/j.adro.2018.08.021eng
hcfmusp.relation.referenceKoks CA, 2015, INT J CANCER, V136, pE313, DOI 10.1002/ijc.29202eng
hcfmusp.relation.referenceKopecka J, 2018, LUNG CANCER, V120, P34, DOI 10.1016/j.lungcan.2018.03.022eng
hcfmusp.relation.referenceKroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008eng
hcfmusp.relation.referenceKrombach J, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1523097eng
hcfmusp.relation.referenceKrysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380eng
hcfmusp.relation.referenceKrysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005eng
hcfmusp.relation.referenceKulzer L, 2014, J IMMUNOTOXICOL, V11, P328, DOI 10.3109/1547691X.2014.880533eng
hcfmusp.relation.referenceKuriakose T, 2018, TRENDS IMMUNOL, V39, P123, DOI 10.1016/j.it.2017.11.002eng
hcfmusp.relation.referenceLabadie BW, 2019, CLIN CANCER RES, V25, P1462, DOI 10.1158/1078-0432.CCR-18-2882eng
hcfmusp.relation.referenceLadoire S, 2015, AUTOPHAGY, V11, P1878, DOI 10.1080/15548627.2015.1082022eng
hcfmusp.relation.referenceLam AR, 2014, CANCER RES, V74, P2193, DOI 10.1158/0008-5472.CAN-13-1703eng
hcfmusp.relation.referenceLan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388eng
hcfmusp.relation.referenceLawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213eng
hcfmusp.relation.referenceLhuillier C, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0653-7eng
hcfmusp.relation.referenceLi CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012eng
hcfmusp.relation.referenceLiikanen I, 2013, MOL THER, V21, P1212, DOI 10.1038/mt.2013.51eng
hcfmusp.relation.referenceLiu CC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00411eng
hcfmusp.relation.referenceLiu P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09415-3eng
hcfmusp.relation.referenceLong Maeve, 2019, Semin Cancer Biol, DOI 10.1016/j.semcancer.2019.05.016eng
hcfmusp.relation.referenceLorenzi S, 2011, J IMMUNOL, V186, P5142, DOI 10.4049/jimmunol.1004163eng
hcfmusp.relation.referenceLu JQ, 2018, ACS NANO, V12, P11041, DOI 10.1021/acsnano.8b05189eng
hcfmusp.relation.referenceLu XY, 2015, J IMMUNOL, V194, P2011, DOI 10.4049/jimmunol.1401894eng
hcfmusp.relation.referenceMa Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003eng
hcfmusp.relation.referenceMa YT, 2011, J EXP MED, V208, P491, DOI 10.1084/jem.20100269eng
hcfmusp.relation.referenceMajeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045eng
hcfmusp.relation.referenceMalaker SA, 2017, CANCER IMMUNOL RES, V5, P376, DOI 10.1158/2326-6066.CIR-16-0280eng
hcfmusp.relation.referenceMalamas AS, 2016, ONCOTARGET, V7, P86937, DOI 10.18632/oncotarget.13520eng
hcfmusp.relation.referenceMandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447eng
hcfmusp.relation.referenceMandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423eng
hcfmusp.relation.referenceMantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012eng
hcfmusp.relation.referenceMartins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75eng
hcfmusp.relation.referenceMartins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500eng
hcfmusp.relation.referenceMartins Isabelle, 2013, Methods Mol Biol, V1004, P43, DOI 10.1007/978-1-62703-383-1_4eng
hcfmusp.relation.referenceMartins I, 2012, AUTOPHAGY, V8, P413, DOI 10.4161/auto.19009eng
hcfmusp.relation.referenceMattei F, 2012, NEOPLASIA, V14, P1223, DOI 10.1593/neo.121444eng
hcfmusp.relation.referenceMcGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012eng
hcfmusp.relation.referenceMcGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018eng
hcfmusp.relation.referenceMcGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490eng
hcfmusp.relation.referenceMcLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318eng
hcfmusp.relation.referenceMcNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787eng
hcfmusp.relation.referenceMelis MHM, 2013, CELL DEATH DIFFER, V20, P765, DOI 10.1038/cdd.2013.8eng
hcfmusp.relation.referenceMelkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431eng
hcfmusp.relation.referenceMenger L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23082eng
hcfmusp.relation.referenceMenger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807eng
hcfmusp.relation.referenceMichaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347eng
hcfmusp.relation.referenceMittal SK, 2015, CURR OPIN IMMUNOL, V34, P22, DOI 10.1016/j.coi.2014.12.009eng
hcfmusp.relation.referenceMoserova I, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1258505eng
hcfmusp.relation.referenceMOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0eng
hcfmusp.relation.referenceMotta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014eng
hcfmusp.relation.referenceMuller LME, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0632-yeng
hcfmusp.relation.referenceMunn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009eng
hcfmusp.relation.referenceMusahl AS, 2015, ONCOGENE, V34, P5046, DOI 10.1038/onc.2014.424eng
hcfmusp.relation.referenceNair-Gupta P, 2014, CELL, V158, P506, DOI 10.1016/j.cell.2014.04.054eng
hcfmusp.relation.referenceNam GH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04607-9eng
hcfmusp.relation.referenceNgwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6eng
hcfmusp.relation.referenceO'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8eng
hcfmusp.relation.referenceObeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201eng
hcfmusp.relation.referenceObeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523eng
hcfmusp.relation.referenceOgawa M, 2017, ONCOTARGET, V8, P10425, DOI 10.18632/oncotarget.14425eng
hcfmusp.relation.referenceOlson B, 2018, CANCER DISCOV, V8, P1358, DOI 10.1158/2159-8290.CD-18-0044eng
hcfmusp.relation.referencePalucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049eng
hcfmusp.relation.referencePanaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67eng
hcfmusp.relation.referencePanaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1eng
hcfmusp.relation.referenceParlato S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01013-xeng
hcfmusp.relation.referencePasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191eng
hcfmusp.relation.referencePfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024eng
hcfmusp.relation.referencePickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603eng
hcfmusp.relation.referencePostow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824eng
hcfmusp.relation.referencePozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078eng
hcfmusp.relation.referencePrestwich RJ, 2008, CLIN CANCER RES, V14, P7358, DOI 10.1158/1078-0432.CCR-08-0831eng
hcfmusp.relation.referenceQuail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009eng
hcfmusp.relation.referenceRadogna F, 2018, BIOCHEM PHARMACOL, V153, P12, DOI 10.1016/j.bcp.2018.02.006eng
hcfmusp.relation.referenceRaposo B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02763-yeng
hcfmusp.relation.referenceRiaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028eng
hcfmusp.relation.referenceRibas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060eng
hcfmusp.relation.referenceRibas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563eng
hcfmusp.relation.referenceRiganti C, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398874eng
hcfmusp.relation.referenceRodriguez-Ruiz ME, 2019, MOL CANCER THER, V18, P621, DOI 10.1158/1535-7163.MCT-18-0558eng
hcfmusp.relation.referenceRodriguez-Ruiz ME, 2016, CANCER RES, V76, P5994, DOI 10.1158/0008-5472.CAN-16-0549eng
hcfmusp.relation.referenceRodriguez-Ruiz ME, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1655964eng
hcfmusp.relation.referenceRomano Erminia, 2018, Oncotarget, V9, P17631, DOI 10.18632/oncotarget.24815eng
hcfmusp.relation.referenceRongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858eng
hcfmusp.relation.referenceRooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033eng
hcfmusp.relation.referenceRubner Y, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-89eng
hcfmusp.relation.referenceRufo N, 2017, TRENDS CANCER, V3, P643, DOI 10.1016/j.trecan.2017.07.002eng
hcfmusp.relation.referenceSabatos-Peyton CA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1385690eng
hcfmusp.relation.referenceSagiv-Barfi I, 2015, BLOOD, V125, P2079, DOI 10.1182/blood-2014-08-593137eng
hcfmusp.relation.referenceSagwal SK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1221-6eng
hcfmusp.relation.referenceSaito Y, 2016, BLOOD, V128, P1829, DOI 10.1182/blood-2015-10-676452eng
hcfmusp.relation.referenceSanti A, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700167eng
hcfmusp.relation.referenceScally SW, 2013, J EXP MED, V210, P2569, DOI 10.1084/jem.20131241eng
hcfmusp.relation.referenceSchaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0eng
hcfmusp.relation.referenceSchiavoni G, 2011, CANCER RES, V71, P768, DOI 10.1158/0008-5472.CAN-10-2788eng
hcfmusp.relation.referenceSchildkopf P, 2011, RADIOTHER ONCOL, V101, P109, DOI 10.1016/j.radonc.2011.05.056eng
hcfmusp.relation.referenceSchumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402eng
hcfmusp.relation.referenceSchumacher TN, 2016, CURR OPIN IMMUNOL, V41, P98, DOI 10.1016/j.coi.2016.07.005eng
hcfmusp.relation.referenceSchumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971eng
hcfmusp.relation.referenceSchuster H, 2017, P NATL ACAD SCI USA, V114, pE9942, DOI 10.1073/pnas.1707658114eng
hcfmusp.relation.referenceSegovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-yeng
hcfmusp.relation.referenceSeitz C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00805eng
hcfmusp.relation.referenceSenovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922eng
hcfmusp.relation.referenceSeo GJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02936-3eng
hcfmusp.relation.referenceShalapour S, 2019, IMMUNITY, V51, P15, DOI 10.1016/j.immuni.2019.06.021eng
hcfmusp.relation.referenceSharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017eng
hcfmusp.relation.referenceShen YJ, 2015, CELL REP, V11, P460, DOI 10.1016/j.celrep.2015.03.041eng
hcfmusp.relation.referenceShimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009eng
hcfmusp.relation.referenceShultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017eng
hcfmusp.relation.referenceShultz Leonard D, 2014, Cold Spring Harb Protoc, V2014, P694, DOI 10.1101/pdb.top073585eng
hcfmusp.relation.referenceShultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311eng
hcfmusp.relation.referenceSicari D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111347eng
hcfmusp.relation.referenceSimpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669eng
hcfmusp.relation.referenceSingh M, 1869, METHOD MOL BIOL, V2019, P231eng
hcfmusp.relation.referenceSistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708eng
hcfmusp.relation.referenceSiurala M, 2015, INT J CANCER, V136, P945, DOI 10.1002/ijc.29048eng
hcfmusp.relation.referenceSmith CC, 2018, J CLIN INVEST, V128, P4804, DOI 10.1172/JCI121476eng
hcfmusp.relation.referenceSoloff AC, 2019, P NATL ACAD SCI USA, V116, P22901, DOI 10.1073/pnas.1916211116eng
hcfmusp.relation.referenceSonnemann J, 2010, CANCER CHEMOTH PHARM, V66, P611, DOI 10.1007/s00280-010-1302-4eng
hcfmusp.relation.referenceSpisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221eng
hcfmusp.relation.referenceSprooten J, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1638212eng
hcfmusp.relation.referenceStarck SR, 2016, IMMUNOL REV, V272, P8, DOI 10.1111/imr.12434eng
hcfmusp.relation.referenceStone JD, 2015, CURR OPIN IMMUNOL, V33, P16, DOI 10.1016/j.coi.2015.01.003eng
hcfmusp.relation.referenceSukkurwala AQ, 2014, CELL DEATH DIFFER, V21, P59, DOI 10.1038/cdd.2013.73eng
hcfmusp.relation.referenceSukkurwala AQ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28473eng
hcfmusp.relation.referenceSuzuki S, 2012, ONCOL REP, V28, P465, DOI 10.3892/or.2012.1831eng
hcfmusp.relation.referenceTaggart D, 2018, P NATL ACAD SCI USA, V115, pE1540, DOI 10.1073/pnas.1714089115eng
hcfmusp.relation.referenceTanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151eng
hcfmusp.relation.referenceTang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5eng
hcfmusp.relation.referenceTang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.xeng
hcfmusp.relation.referenceTaniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142eng
hcfmusp.relation.referenceTeo ZL, 2017, CANCER RES, V77, P6340, DOI 10.1158/0008-5472.CAN-17-2210eng
hcfmusp.relation.referenceTesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356eng
hcfmusp.relation.referenceTorchinsky MB, 2009, NATURE, V458, P78, DOI 10.1038/nature07781eng
hcfmusp.relation.referenceTruxova I, 2020, HAEMATOLOGICA, V105, P1868, DOI 10.3324/haematol.2019.223933eng
hcfmusp.relation.referenceTufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275eng
hcfmusp.relation.referenceTuran T, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0355-5eng
hcfmusp.relation.referenceTwyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292eng
hcfmusp.relation.referenceVacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779eng
hcfmusp.relation.referenceVan Hoecke L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05979-8eng
hcfmusp.relation.referencevan Lummel M, 2014, DIABETES, V63, P237, DOI 10.2337/db12-1214eng
hcfmusp.relation.referencevan Schadewijk A, 2012, CELL STRESS CHAPERON, V17, P275, DOI 10.1007/s12192-011-0306-2eng
hcfmusp.relation.referenceVancsik T, 2018, J CANCER, V9, P41, DOI 10.7150/jca.21520eng
hcfmusp.relation.referenceVanpouille-Box C, 2019, NAT REV DRUG DISCOV, V18, P845, DOI 10.1038/s41573-019-0043-2eng
hcfmusp.relation.referenceVanpouille-Box C, 2018, CANCER CELL, V34, P361, DOI 10.1016/j.ccell.2018.05.013eng
hcfmusp.relation.referenceVanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618eng
hcfmusp.relation.referenceVanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511eng
hcfmusp.relation.referenceVenereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189eng
hcfmusp.relation.referenceVentura A, 2018, CANCER RES, V78, P4045, DOI 10.1158/0008-5472.CAN-18-0171eng
hcfmusp.relation.referenceVesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324eng
hcfmusp.relation.referenceVijayan D, 2017, NAT REV CANCER, V17, P709, DOI 10.1038/nrc.2017.86eng
hcfmusp.relation.referenceVitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001eng
hcfmusp.relation.referenceVitale I, 2019, TRENDS CELL BIOL, V29, P396, DOI 10.1016/j.tcb.2019.01.003eng
hcfmusp.relation.referenceVoorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4eng
hcfmusp.relation.referenceVoron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559eng
hcfmusp.relation.referenceWaldmann H, 2010, NAT REV NEPHROL, V6, P569, DOI 10.1038/nrneph.2010.108eng
hcfmusp.relation.referenceWalsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332eng
hcfmusp.relation.referenceWang HM, 2015, INT J MOL SCI, V16, P3391, DOI 10.3390/ijms16023391eng
hcfmusp.relation.referenceWang L, 2019, SCIENCE, V365, P656, DOI 10.1126/science.aav0758eng
hcfmusp.relation.referenceWculek SK, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0565-5eng
hcfmusp.relation.referenceWEBER J, 1994, CANCER RES, V54, P1766eng
hcfmusp.relation.referenceWeiss EM, 2010, J IMMUNOTOXICOL, V7, P194, DOI 10.3109/15476911003657414eng
hcfmusp.relation.referenceWellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004eng
hcfmusp.relation.referenceWemeau M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.82eng
hcfmusp.relation.referenceWerthmoller N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.129eng
hcfmusp.relation.referenceWest AC, 2013, CANCER RES, V73, P7265, DOI 10.1158/0008-5472.CAN-13-0890eng
hcfmusp.relation.referenceWherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862eng
hcfmusp.relation.referenceWoller N, 2015, MOL THER, V23, P1630, DOI 10.1038/mt.2015.115eng
hcfmusp.relation.referenceWu JJ, 2018, CANCER LETT, V419, P210, DOI 10.1016/j.canlet.2018.01.050eng
hcfmusp.relation.referenceYamauchi M, 2018, J CLIN INVEST, V128, P16, DOI 10.1172/JCI93554eng
hcfmusp.relation.referenceYamazaki T, 2014, CELL DEATH DIFFER, V21, P69, DOI 10.1038/cdd.2013.72eng
hcfmusp.relation.referenceYang D, 2017, IMMUNOL REV, V280, P41, DOI 10.1111/imr.12577eng
hcfmusp.relation.referenceYang H, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1149673eng
hcfmusp.relation.referenceYang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107eng
hcfmusp.relation.referenceYang MH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431086eng
hcfmusp.relation.referenceYatim N, 2015, SCIENCE, V350, P328, DOI 10.1126/science.aad0395eng
hcfmusp.relation.referenceYatim N, 2011, IMMUNITY, V35, P478, DOI 10.1016/j.immuni.2011.10.010eng
hcfmusp.relation.referenceZamarin D, 2014, SCI TRANSL MED, V226, pra32eng
hcfmusp.relation.referenceZappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005eng
hcfmusp.relation.referenceZervoudi E, 2013, P NATL ACAD SCI USA, V110, P19890, DOI 10.1073/pnas.1309781110eng
hcfmusp.relation.referenceZhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780eng
hcfmusp.relation.referenceZhou H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.47eng
hcfmusp.relation.referenceZhou H, 2016, CELL DEATH DIFFER, V23, P2031, DOI 10.1038/cdd.2016.86eng
hcfmusp.relation.referenceZitvogel L, 2016, NAT REV CANCER, V16, P759, DOI 10.1038/nrc.2016.91eng
hcfmusp.relation.referenceZitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845eng
hcfmusp.relation.referenceZschaler J, 2014, CRIT REV IMMUNOL, V34, P433eng
dc.description.indexMEDLINEeng
dc.identifier.eissn2051-1426
hcfmusp.citation.scopus603-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_GALLUZZI_Consensus_guidelines_for_the_definition_detection_and_interpretation_2020.PDFpublishedVersion (English)1.63 MBAdobe PDFThumbnail
View/Open
Show simple item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.